The comparison of red cell indices amongst different groups of reference samples, beta-thalassemia carriers and carriers of SUPT5H variants and compound heterozygotes provided more insight into the clinical phenotype of reduced SUPT5H expression. This evidence concerns the gene SUPT5H and Beta-thalassemia.